The payments were received for getting Sativex approved for use in dealing with cancer-related pain. GW Pharmaceuticals posted impressive sales of Epidiolex, a cannabis derived drug. The company achieved European approval for this drug last year for treating effects of multiple sclerosis. If you have an interest in the lucrative microcap sector, sign up to Insider Financial today.
GW Pharmaceuticals and Greenwich Biosciences, the US subsidiary, will showcase the phase 3 clinical trials of oral solution – Epiodiolex at AAN (American Academy of Neurology) annual conference in Philadelphia on May 4, 2019. RLFTF remains one of our favorite COVID-19 plays here at Insider Financial. The offering is expected to close Sept. 25.On The Radar Clinical Readouts GlycoMimetics Inc (NASDAQ: GLYC) will present at the 2020 American Academy of Neurology, or AAN, Science Highlights, a poster on data from a post hoc analysis of the Phase 3 RESET trial that evaluated rivipansel as a treatment option for acute vaso-occlusion in sick cell disease patients requiring hospitalization for treatment.Axsome Therapeutics Inc (NASDAQ: AXSM) will present at the AAN meeting already-released Phase 3 data for AXS-07 in migraine.Earnings Centogene (before the market open)See more from Benzinga * The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout * The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix * The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations(C) 2020 Benzinga.com. Here are two FTSE 100 (INDEXFTSE: UKX) dividend stocks that could benefit. Marijuana stocks have soared, and for good reason. Get stock alerts, news & related alerts straight to your inbox! The published article features commentary from Hemp, Inc. CEO, Bruce Perlowin, regarding the uncertainty of the cannabis industry with a federal ban on the product and massive costs that many investors did not anticipate. Japanese drug maker Otsuka has obtained the exclusive rights to develop and commercialize Sativex in the U.S. News of Epidiolex And On Posting Impressive Results, GW Pharmaceuticals Plc (OTCMKTS:GWPRF) Records Weekly Gains of 10% in Stock Price. View real-time stock prices and stock quotes for a full financial overview. The company began the sales of Epidiolex in November 2018. In our last profile of the company, we focused on... Let’s face it, COVID-19 isn’t going away anytime soon.
The Epidiolex program has expanded into clinical studies in Europe and the U.S., and is expected to be completed in 2016. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Marijuana June 11, 2020July 19, 2020 With recent changes to regulations regarding hemp across the United States, interest in marijuana stocks is at an all-time high. Nashville, TN – GW PHARMACEUTICALS (OTCMKTS:GWPRF) recently reported its fiscal 2014 results highlighted by solid…, GW Pharmaceuticals plc (NASDAQ:GWPH) has presented new encouraging data from two Phase 3 clinical trials…, Your email address will not be published. The initiation of the trial follows positive interim results from the Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.Based on these results and following discussions with the FDA, the company plans to enroll up to 60,000 volunteers across three continents to study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19.J&J shares were rising 2.73% to $148.14.MediciNova's Intranasal COVID-19 Vaccine Candidate Produces Positive Results In Animal Studies MediciNova, Inc. (NASDAQ: MNOV) said its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen (Ag) of SARS-CoV-2 in mice.View more earnings on IBBMediciNova shares were surging up 21.66% to $6.44.GW Pharma Epidiolex Gets Regulatory Nod In Australia GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) said the Australian Therapeutic Goods Administration has approved Epidyolex for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age and older.This represents the CBD drug's third global regulatory approval, following FDA approval in 2018 and European Commission approval in 2019.Centogene Expands COVID Testing Facility to Dusseldorf Airport Centogene NV (NASDAQ: CNTG) announced today the opening of its new COVID-19 testing facility at Dusseldorf Airport.
GW Pharmaceuticals plans for the launch of an oral solution – Epidiolex in the five major markets of Europe in the later part of 2019. Despite the stock market being somewhat confusing for most people, companies are making it more... Hemp, Inc. CEO Bruce Perlowin Featured in Sinclair Broadcast Coverage About Hemp Stocks Amidst a Congressional Push for Legalization December 3, 2019December 10, 2019 The published article features commentary from Hemp, Inc. CEO, Bruce Perlowin, regarding the uncertainty of the cannabis industry with a federal ban on the product and massive costs that many investors did not anticipate.Read more...WeedMD Reports Third Quarter 2019 Financial Results and Announces Strategic Combination with Starseed November 29, 2019December 3, 2019 WeedMD Inc. reports net revenues of $6.7 million with a gross margin of 29%.